The final results of the Clinical Trial of COVID-19 Convalescent Plasma in Outpatients (C3PO) demonstrate that COVID-19 convalescent plasma did not prevent disease progression in a high-risk group of outpatients with COVID-19 when administered within the first week of their symptoms.
As reported in an Original Research article published by the NEJM on August 18, 2021, the trial was stopped in February 2021 due to a lack of efficacy based on a planned interim analysis.
Convalescent Plasma Failed to Deliver Significant Benefits for High-Risk COVID-19 Outpatients
Screening Mammograms Plummeted During COVID-19 Pandemic
Drop in breast cancer screenings at one safety-net hospital raises concerns for worsening of preexisting health disparities
mRNA COVID-19 Vaccine Effectiveness Lower During Delta Strain Era
Adjusted effectiveness 53.1 percent against infection in nursing home residents during period when delta strain was predominant
mRNA Vaccine Effective Against Hospitalization Over 24-Week Period
Pfizer-BioNTech and Moderna vaccines effective against COVID-19-associated hospitalizations among adults
Physician’s Briefing Weekly Coronavirus Roundup
Here is what the editors at Physician’s Briefing chose as the most important COVID-19 developments for you and your practice for the week of Aug. 16 to 20, 2021. This …
Long-Haul COVID-19 May Affect Two of Three With Mild, Moderate Disease
Authors say these estimates are similar to estimates in hospitalized patients
COVID-19 Immune Response Appears Strong in Cancer Patients
Vast majority show seropositivity four months after the second COVID-19 vaccine dose
Risk for Myocarditis in Young Who Get Moderna Shots May Be Greater Than Thought
However, health officials emphasize that COVID-19 puts someone at much greater risk for heart inflammation than getting the vaccine does
Decision on J&J COVID-19 Vaccine Booster Doses Could Take Weeks
Federal health officials are waiting on results from a government-backed clinical trial and from studies by Johnson & Johnson